Navigation Links
New Biotech Drugs to Aid in Renal Cell Carcinoma Treatment

Two biotech drugs produced by Bayer AG, Pfizer and Onyx pharmaceuticals are astounding doctors with their effects on decreasing the progression// of metastatic kidney cancer.

The drugs, sunitinib (marketed under brand name Sutent) and sorafenib (brand name Nexavar) have been found to delay the progression of renal cell carcinoma by 3 to 6 months.

Renal cell carcinoma is the most common of all kidney cancers; 90 percent of kidney cancers diagnosed in the US are due to this cancer. It is responsible for 1.5 percent of all cancer deaths and around 30,000 cases of renal cell carcinoma are diagnosed every year.

The standard drugs used are interferon alfa and interleukin-2. Yet these drugs help in only 5 percent of cases where the tumors have spread. Hence the excitement over the new drugs.

Researchers from US, France and Poland, contributed to the results of the study published in the New England Journal of Medicine.

The studies report how sunitinib when given to patients slowed the progression of the disease or development of tumors, to 11 months as against 5 months with interferon alfa. This was tested on 375 cancer patients.

In the case of sorafenib, half of 903 volunteers from 19 countries were put on the drug, while the other half received a placebo. Those who took the drug showed an extra period of around 3 months in delay of tumor growth.

The results were so effective that doctors are now thinking of placing the control patients on the drug.

Yet side effects of the drugs persist and can be severe in some patients. They include skin rashes, diarrhea and increased blood pressure.

Both drugs work by inhibiting the blood flowing to the tumor and hence limiting its growth.

"Kidney cancer has always been regarded as a cancer in which there was no progress," explains the lead author of the sunitinib study, Dr. Robert Motzer from Memorial Sloan-Kettering Cancer Center in Ne w York City. "Based on a better understanding of tumor biology, this new medication (sunitinib) was developed, and it has remarkable activity that has resulted in a complete change in the way we treat this cancer."

Dr. James Brugarolas from the University of Texas Southwestern Medical Center, another researcher, adds,” The two new drugs represent a major step forward in our fight against kidney cancer that was made possible by obtaining a greater understanding of the molecular genetics and biology of the disease. These drugs are clearly effective against the tumor.”
AN
'"/>




Related medicine news :

1. Biotechnology industry expected to grow into a three billion dollar industry by 2002
2. Biotechnology on the lead
3. Panacea Biotech To Market Anthrax Vaccine
4. Commercialization of Biotech Discoveries, An Encouragement For Researchers
5. Biotech drug causing anemia-EPREX
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Biologicals Transfer Proposal between US and Indian Biotechnology
8. Vical Biotech and NIH jointly develops HIV vaccine
9. Biotechnology Initiatives Planned In Hyderabad
10. Biotech Osiris to go public
11. Western Region Tops in Indian Biotech Growth
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/15/2018)... ... , ... Through its Microbiome Grant Initiative , uBiome, the leader in ... analysis to a team of UCLA Department of Urology researchers led by Dr. William ... microbiome of a low-fat diet supplemented with fish oil in patients diagnosed with localized ...
(Date:11/15/2018)... ... November 15, 2018 , ... ... the release of “Loneliness in Our Human Code”, ( https://www.goinvo.com/vision/loneliness-in-our-human-code/ ) the latest ... of Health. This visual essay explores how social determinants of health, with a ...
(Date:11/14/2018)... ... November 14, 2018 , ... Racial ... areas and in regions experiencing shortages. The Association of American Medical Colleges ... populations , Researchers from the American Board of Family Medicine (ABFM) aggregated racial ...
(Date:11/14/2018)... ... 2018 , ... PAINWeekEnd on Saturday, December 1, at the Hyatt Regency Baltimore ... providing busy clinicians and allied healthcare practitioners with 6.0 hours of relevant, practical instruction ... Drug Abuse, Maryland is among the top five states in the nation in the ...
(Date:11/14/2018)... ... ... The Austin-area sports medicine team at Medicine in Motion is reminding ... plan paperwork to review coverage and assess how many unused insurance benefits remains. Whether ... by taking a few minutes for an insurance plan evaluation. , “With the ...
Breaking Medicine News(10 mins):
(Date:11/13/2018)... NASHVILLE, Tenn. (PRWEB) , ... November 13, 2018 ... ... Group, has joined the Center for Medical Interoperability Board. , “We are ... care of people can seamlessly exchange information and be easily swapped out as ...
(Date:11/13/2018)... ... November 13, 2018 , ... ... new features to its flagship solution, MCenter™, that support a wider variety of ... companies and AI service providers. , “By partnering with our customers and ...
(Date:11/13/2018)... ... November 13, 2018 , ... Intrepy Healthcare ... SEO, social media, digital advertising and physician liaison services is announcing the launch ... looking to successfully grow their practice can visit the new Intrepy Healthcare ...
Breaking Medicine Technology: